Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 3-10 (IGHD3-10) is one of the diversity (D) gene segments within the immunoglobulin heavy chain (IGH) locus on human chromosome 14q32.33. The IGHD gene segments, including IGHD3-10, are involved in the somatic recombination process during B-cell development, where one variable (V), one diversity (D), and one joining (J) segment are assembled to encode the variable region of immunoglobulin heavy chains. This combinatorial process underlies the vast diversity of antibodies in the adaptive immune system. IGHD3-10 itself is a short, non-coding DNA segment that becomes part of the third complementarity-determining region (CDR-H3) of the antibody, which is critical for antigen binding. The gene is not a receptor, enzyme, transporter, or direct therapeutic target, but is essential in generating antibody diversity. It is not directly associated with specific diseases, nor targeted by drugs, biomarkers, or recognized for safety issues. Key Points: - IGHD3-10 is a germline gene segment rather than a full-length gene or protein. - Its function is to provide diversity to the antibody repertoire through V(D)J recombination, crucial for humoral immunity. - It is not a therapeutic target nor implicated in diseases directly; thus, there are no known interacting drugs, mechanisms of action, or clinical biomarkers associated specifically with IGHD3-10.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 3-10 (IGHD3-10).